Get the Stockscreener App
6.06
20.96%
1.05
After Hours:
6.02
-0.04
-0.66%
Ardelyx Inc stock is traded at $6.06, with a volume of 18.71M.
It is up +20.96% in the last 24 hours and up +9.98% over the past month.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
See More
Previous Close:
$5.01
Open:
$6.43
24h Volume:
18.71M
Relative Volume:
4.82
Market Cap:
$1.46B
Revenue:
$386.15M
Net Income/Loss:
$-56.39M
P/E Ratio:
-26.35
EPS:
-0.23
Net Cash Flow:
$-55.19M
1W Performance:
+20.24%
1M Performance:
+9.98%
6M Performance:
+10.08%
1Y Performance:
+3.24%
1-Day Range:
$5.86
$6.73
1-Week Range:
$4.91
$6.73
52-Week Range:
$3.21
$6.78
Ardelyx Inc Stock (ARDX) Company Profile
Name
Ardelyx Inc
Sector
Industry
Phone
510-745-7047
Address
34175 ARDENWOOD BLVD., FREMONT, CA
Compare ARDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
6.06 | 1.21B | 386.15M | -56.39M | -55.19M | -0.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Resumed | Raymond James | Strong Buy |
| Jun-18-25 | Resumed | H.C. Wainwright | Buy |
| May-02-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-07-25 | Resumed | Ladenburg Thalmann | Buy |
| Mar-04-25 | Initiated | BTIG Research | Buy |
| Nov-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-02-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Apr-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-18-23 | Initiated | Raymond James | Strong Buy |
| Sep-07-23 | Initiated | H.C. Wainwright | Buy |
| Aug-25-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-03-23 | Upgrade | Wedbush | Neutral → Outperform |
| Nov-17-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-01-21 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Oct-14-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jul-21-21 | Downgrade | Jefferies | Buy → Hold |
| Jul-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-20-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-23-21 | Initiated | Wedbush | Outperform |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-20-20 | Resumed | Citigroup | Buy |
| Feb-18-20 | Resumed | Jefferies | Buy |
| Feb-12-20 | Initiated | Citigroup | Buy |
| Feb-10-20 | Initiated | Cowen | Outperform |
| Apr-08-19 | Initiated | Piper Jaffray | Overweight |
| Aug-24-18 | Initiated | Jefferies | Buy |
| Mar-19-18 | Resumed | Leerink Partners | Outperform |
| Nov-29-17 | Reiterated | Citigroup | Buy |
| Nov-22-17 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-17-17 | Resumed | Leerink Partners | Outperform |
| Mar-31-16 | Initiated | Ladenburg Thalmann | Buy |
| Mar-09-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-03-16 | Initiated | Citigroup | Buy |
View All
Ardelyx Inc Stock (ARDX) Latest News
How currency fluctuations impact Ardelyx Inc. stockPortfolio Update Report & Community Trade Idea Sharing Platform - newser.com
Backtesting results for Ardelyx Inc. trading strategies2025 Winners & Losers & Low Risk Investment Opportunities - newser.com
Should you hold or exit Ardelyx Inc. nowJuly 2025 Opening Moves & Weekly High Return Stock Forecasts - newser.com
Ardelyx (NASDAQ:ARDX) Releases Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Analyst Estimates: Here's What Brokers Think Of Ardelyx, Inc. (NASDAQ:ARDX) After Its Third-Quarter Report - simplywall.st
Ardelyx Stock Surges on Strong Q3 Performance and Future Optimism - StocksToTrade
Ardelyx Stock Soars After Beating Expectations: What’s Next? - timothysykes.com
Why Ardelyx (ARDX) Is Up 20.2% After Positive IBSRELA Patient Data at ACG 2025 Conference - Yahoo Finance
What high frequency data says about Ardelyx Inc.Trade Volume Summary & Weekly High Return Forecasts - newser.com
Ardelyx (NASDAQ:ARDX) Share Price Passes Above 50 Day Moving AverageHere's What Happened - MarketBeat
Forecasting Ardelyx Inc. price range with options dataJuly 2025 Review & Consistent Income Trade Ideas - newser.com
Is Ardelyx Inc. (41X) stock ideal for retirement investorsWall Street Watch & Safe Capital Growth Tips - newser.com
Ranking Ardelyx Inc. among high performing stocks via tools2025 Short Interest & Daily Volume Surge Trade Alerts - newser.com
What analysts say about Ardelyx Inc stockSmall Cap Stock Opportunities & Affordable Portfolio Strategies - earlytimes.in
Ardelyx, Inc. (NASDAQ:ARDX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Ardelyx raises 2025 IBSRELA revenue guidance to $270M-$275M as growth accelerates - MSN
Ardelyx (NASDAQ:ARDX) Given New $10.00 Price Target at TD Cowen - MarketBeat
Investors Buy Large Volume of Call Options on Ardelyx (NASDAQ:ARDX) - MarketBeat
Ardelyx (NASDAQ:ARDX) Shares Gap UpShould You Buy? - MarketBeat
Ardelyx Stock Surges as Q3 Earnings Exceed Expectations - StocksToTrade
Ardelyx, Inc. (NASDAQ:ARDX) Q3 2025 Earnings Call Transcript - Insider Monkey
symbol__ Stock Quote Price and Forecast - CNN
Ardelyx Reports Strong Q3 Growth and Pipeline Expansion - The Globe and Mail
Ardelyx (ARDX): Forecasted 20% Revenue Growth and Profitability Timeline Shape Investor Expectations Ahead of Earnings - simplywall.st
Ardelyx Inc. Reports Strong Q3 Earnings Growth - TipRanks
Ardelyx (ARDX) Receives a Boost in Price Target from TD Cowen | - GuruFocus
Ardelyx Inc (41X.SG) stock price, news, quote and history - Yahoo! Finance Singapore
Ardelyx Shares Soar Premarket As CEO Sees Continued Demand For Blockbuster Drug Ibsrela - MSN
Ardelyx’s Strategic Growth and Pipeline Potential Justify Buy Rating - TipRanks
Ardelyx’s Strong Financial Performance and Growth Potential Drive Buy Rating - TipRanks
Is Ardelyx Inc. stock overvalued by current metricsMarket Growth Report & Community Consensus Picks - newser.com
Order flow analysis tools used on Ardelyx Inc.2025 Trading Volume Trends & Precise Trade Entry Recommendations - newser.com
Ardelyx: Q3 Earnings Snapshot - theheraldreview.com
Why Amazon Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket - Benzinga
Ardelyx Q3 Breakeven, Revenue Increases; Shares Rise Pre-Bell - MarketScreener
Can Ardelyx Inc. stock beat market expectations this quarterJuly 2025 Weekly Recap & Real-Time Chart Pattern Alerts - newser.com
Analyzing drawdowns of Ardelyx Inc. with statistical toolsInflation Watch & Fast Entry Momentum Alerts - newser.com
Will Ardelyx Inc. stock benefit from commodity pricesRate Hike & Safe Entry Point Alerts - newser.com
Ardelyx Inc (ARDX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Market Challenges - Investing.com Canada
Earnings call transcript: Ardelyx Q3 2025 revenue beats forecast, stock stable - Investing.com Canada
Ardelyx (ARDX) Reports Strong Q3 Growth, Raises Full-Year Guidan - GuruFocus
Transcript : Ardelyx, Inc., Q3 2025 Earnings Call, Oct 30, 2025 - MarketScreener
Ardelyx (ARDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - sharewise.com
Ardelyx Rides IBSRELA Demand To A Revenue Jump - Finimize
Ardelyx, Inc. (ARDX) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Ardelyx’s Strong Market Performance and Growth Potential Justify Buy Rating and Raised Price Target - TipRanks
Ardelyx reports Q3 EPS 0c, consensus (7c) - TipRanks
Ardelyx Inc Stock (ARDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):